Renal Phenotype Variations among Families with Autosomal Alport Syndrome: Potential Role of Modifier Genes.

KEY POINTS

Modifying genes may alter the phenotype of patients with Alport syndrome. There is intrafamilial and interfamilial phenotype variation in Alport syndrome.

BACKGROUND

Alport syndrome (AS) is an inherited disorder characterized by progressive kidney disease, hearing deficits, and ocular abnormalities. This study investigates phenotypic variability among individuals with identical autosomal genetic mutations in and explores the potential influence of modifier genes. The study focuses on three families carrying the same mutation (, ), but exhibiting differences in phenotype. The objective was to elucidate interfamilial and intrafamilial variations and identify potential genetic modifiers contributing to these differences.

METHODS

Three families from a cohort at the University of Utah were studied. Clinical data, blood, urine, and tissue samples were collected with informed consent. Whole-exome sequencing was performed to identify genetic variants, using the SureSelect Human All Exon Target Enrichment System. Variant calling and annotation were conducted with Genome Analysis Tool Kit, variant effect predictor, and PEDDY. Disease–gene prioritization was achieved using the Variant Annotation, Analysis, and Search Tool; Pedigree Variant Annotation, Analysis, and Search Tool; and the Phenotype Driven Variant Ontological Reranking Tool. Modifier genes were identified through cosegregation analysis and functional annotation using public databases.

RESULTS

The study highlighted significant phenotypic variability within and between families with the same mutation. Individuals with single mutations often presented mild phenotypes, such as isolated hematuria, whereas compound heterozygotes and digenic cases exhibited severe manifestations, including proteinuria, hearing loss, and CKD. Modifier genes such as GRIP1, CCND1, and CYP3A7 were identified and linked to phenotypic variability, suggesting their potential role in disease progression.

CONCLUSIONS

The findings underscore the role of genetic modifiers in influencing phenotypic variability in AS. Understanding these modifiers is crucial for personalized therapeutic strategies and genetic counseling. Future research should validate these candidate genes through functional studies and larger cohorts to enhance clinical care and improve prognostic predictions for patients with AS.